Comparative Pharmacology
Head-to-head clinical analysis: CARTIA XT versus PROCARDIA XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARTIA XT versus PROCARDIA XL.
CARTIA XT vs PROCARDIA XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.
30-90 mg orally once daily, extended-release tablet.
None Documented
None Documented
Terminal half-life 3-4.5 hours; prolonged in hepatic impairment (up to 15 hours) or with cimetidine.
Terminal elimination half-life: 6-11 hours; clinical context: steady-state achieved after 2-3 days of once-daily dosing.
Renal (biliary/fecal minimal). 70-80% excreted as inactive metabolites in urine; 15% unchanged.
Renal: 70-80% as metabolites, <1% unchanged; Fecal: 15-20% via bile.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker